BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivozanib: Phase Ib data

Preliminary data from 18 patients in the Phase Ib portion of the ongoing, open-label, international Phase Ib/IIa AVI-951-08-104 trial showed that oral AV-951 plus paclitaxel produced an ORR of 28% with 5 partial responses after a mean treatment duration of 22.2 weeks. Additionally, 44% of patients achieved disease control....

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >